Cite
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50
MLA
Cortellini, A., et al. Clinicopathologic Correlates of First-Line Pembrolizumab Effectiveness in Patients with Advanced NSCLC and a PD-L1 Expression of ≥ 50. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1415731481&authtype=sso&custid=ns315887.
APA
Cortellini, A., Tiseo, M., Banna, G., Cappuzzo, F., Aerts, J., Barbieri, F., Giusti, R., Bria, E., Cortinovis, D., Grossi, F., Migliorino, M., Galetta, D., Passiglia, F., Santini, D., Berardi, R., Morabito, A., Genova, C., Mazzoni, F., Di Noia, V., … Porzio G. (2020). Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Chicago
Cortellini, A, M Tiseo, G Banna, F Cappuzzo, J Aerts, F Barbieri, R Giusti, et al. 2020. “Clinicopathologic Correlates of First-Line Pembrolizumab Effectiveness in Patients with Advanced NSCLC and a PD-L1 Expression of ≥ 50.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1415731481&authtype=sso&custid=ns315887.